EcoDrugPlus

Opioid Receptor, Mu 1

Ensembl ID : ENSATEG00000009728
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSATEG00000005254
Gene Symbol: OXTR
3 Cross references
193 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSATEG00000005072
Gene Symbol: PAK4
1 Cross references
163 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSATEG00000005394
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSATEG00000024979
Gene Symbol: PPARG
4 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSATEG00000009775
Gene Symbol: PPARAA
1 Cross references
384 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSATEG00000019787
Gene Symbol: PPARAB
3 Cross references
397 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSATEG00000020562
Gene Symbol: PPARDB
3 Cross references
392 Possible Orthologues:

Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform

Ensembl ID : ENSATEG00000022254
Gene Symbol: LOC113152346
2 Cross references
202 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSATEG00000020692
Gene Symbol: PIK3CA
4 Cross references
194 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSATEG00000021657
Gene Symbol: PIK3CB
1 Cross references
217 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSATEG00000018121
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).